FS Investments plans to relocate from the Philadelphia Navy Yard to Brandywine Realty Trust’s new $300 million mixed-use tower at ... by Swiss pharmaceutical giant Roche for $4.8 billion in ...

Brandywine Realty Trust, the dominant commercial landlord in Center City and the Main Line suburbs, last fall delayed plans for a life sciences-focused tower at ... at Roche’s Spark Therapeutics.

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Inc, Sunovion Pharm. Inc, Suven pharmaceutical company, Roche pharmaceutical company, Biogen pharmaceutical company, Synexus clinical research organization and tauX pharmaceutical company and ...

Earnings per share (EPS) missed analyst estimates by 38%. The primary driver behind last 12 months revenue was the Pharmaceuticals - Roche Pharmaceuticals segment contributing a total revenue of CHF46 ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Sales in Roche’s pharmaceutical division grew 8% to CHF 46.2bn ($50.9bn). Credit: hapabapa via Getty Images. Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), ...